

Liver disease and HIV/HBV co-infection in the era of HAART

STUDY TITLE:	Liver disease and HIV/HBV co-infection in the era of HAART
STUDY OBJECTIVE:	The purpose of this study is to investigate chronic hepatitis B in HIV-infected persons receiving highly active antiretroviral therapy (HAART).
STUDY DESIGN:	Study participants will be followed over a period of 5 years to observe their HIV and Hepatitis B infection.
STUDY DRUGS:	There are no treatment requirements for the study. Participants will continue to be treated as usual by their treating physician.
STUDY COMPLETION DATE:	Recruitment closed. Follow-up continues to 2009
IS THE STUDY OPEN TO ENROLLMENT?	No To enter the study you must be an adult infected with hepatitis B virus and HIV and currently taking highly active antiretroviral therapy OR planning to commence highly active antiretroviral therapy within 1 year. If you have a history of hepatitis C infection, you will be unable to participate in the study.
NUMBER OF PATIENTS ENROLLED/TARGET ENROLLMENT:	70/70
SPONSOR:	National Institutes of Health (NIH), U.S.A
PARTICIPATING SITES:	St Vincent's Hospital, Sydney Royal Melbourne Hospital, Melbourne The Alfred Hospital, Melbourne MACS cohort, John Hopkins University, Baltimore, USA
CONTACT PERSON:	Pip Marks (02) 9385 0886